The expression of PRAME in chronic lymphoproliferative disorders

Leukemia Research

Volumn 27, Issue 5, 2003, Pages 393-396

  Proto Siqueira, Rodrigo ^a   Falcão, Roberto Passetto ^a   De Souza, Carmino Antonio ^b   Ismael, Sebastião José ^a   Zago, Marco Antonio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Chronic lymphoproliferative disorders; Immunotherapy; Minimal residual disease; PRAME

Indexed keywords

ANTIGEN; PROTEIN; PROTEIN PRAME; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CHRONIC DISEASE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; CHRONIC DISEASE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, PROLYMPHOCYTIC; LYMPHOMA, MANTLE-CELL; LYMPHOPROLIFERATIVE DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0037400598     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00217-5     Document Type: Article

References (11)

1. Matsushita M., Ikeda H., Kizaki M., Okamoto S., Ogasawara M., Ikeda Y.et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br. J. Haematol. 112:2001;916-926.
2. Ikeda H., Lethé B., Lehmann F., van Baren N., Baurain J.F., De Smet C.et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:1997;199-208.
3. van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I.et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol. 102:1998;1376-1379.
4. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U.et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp. Hematol. 28:2000;1413-1422.
5. van Baren N., Brasseur F., Godelaine D., Hames G., Ferrant A., Lehmann F.et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 94:1999;1156-1164.
6. *)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193:2001;73-88.
7. Lethé B., van der Bruggen P., Brasseur F., Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res. 7(Suppl. 2):1997;S83-S88.
8. Watari K., Tojo A., Nagamura-Inoue T., Nagamura F., Takeshita A., Fukushima T.et al. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett. 466:2000;367-371.
9. De S., Lurquin C., Lethe B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19:1999;7327-7335.
10. Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P.et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer. 86:2002;979-982.
11. Steinbach D., Hermann J., Viehmann S., Zintl F., Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet. Cytogenet. 133:2002;118-230.